| 产品编号 | CFN60062 | |
| CAS编号 | 936727-05-8 | |
| 分子式 = 分子量 | C24H18F2N2O5 = 452.41 | |
| 产品纯度 | >=98% | |
| 物理属性 | Powder | |
| 化合物类型 | Alkaloids | |
| 植物来源 | ||
| ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用 | ||
| 产品名称 | 产品编号 | CAS编号 | 包装 | QQ客服 |
| 鲁玛卡托 | CFN60062 | 936727-05-8 | 1mg | QQ客服:3004468088 |
| 鲁玛卡托 | CFN60062 | 936727-05-8 | 5mg | QQ客服:3004468088 |
| 鲁玛卡托 | CFN60062 | 936727-05-8 | 10mg | QQ客服:3004468088 |
| 鲁玛卡托 | CFN60062 | 936727-05-8 | 20mg | QQ客服:3004468088 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)| Description: | VX-809 (Lumacaftor, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. |
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2104 mL | 11.0519 mL | 22.1038 mL | 44.2077 mL | 55.2596 mL |
| 5 mM | 0.4421 mL | 2.2104 mL | 4.4208 mL | 8.8415 mL | 11.0519 mL |
| 10 mM | 0.221 mL | 1.1052 mL | 2.2104 mL | 4.4208 mL | 5.526 mL |
| 50 mM | 0.0442 mL | 0.221 mL | 0.4421 mL | 0.8842 mL | 1.1052 mL |
| 100 mM | 0.0221 mL | 0.1105 mL | 0.221 mL | 0.4421 mL | 0.5526 mL |
| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 氧氟草苷B; Oxytroflavoside B | CFN95490 | 1391144-81-2 | C34H40O19 = 752.7 | 10mg | QQ客服:3004468091 |
| 奥苷菊环; Bicyclo[5.3.0]decapentaene | CFN70091 | 275-51-4 | C10H8 = 128.1 | 20mg | QQ客服:3004468091 |
| 4-硝基苯甲醇氨基甲酸酯; 4-Nitrobenzyl carbamate | CFN92319 | 32339-07-4 | C8H8N2O4 = 196.2 | 5mg | QQ客服:3004468088 |
| 3'-二甲氧基荜茇明碱; 3'-Demethoxypiplartine | CFN96121 | 130263-10-4 | C16H17NO4 = 287.3 | 5mg | QQ客服:3004468091 |